Skip to content
DataLookout
Start free
Menu

HCV/CKDNCT07770984

Treatment of CKD Patients With HCV

StatusNot Yet Recruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Study description shortened, about 162 wordsv3
  2. Secondary endpoints: details revised at 1 of 1 entry
    • Study description expanded, about 76 words
    v2
  3. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Treatment efficacy
Timeframe: 12 weeks

Secondary (1)

Treatment safety

Arms and interventions

HCV patients with GFR more than 30ml/minActive comparator

25 CKD Patients with eGFR˃30ml/min with HCV infection and will receive one oral tablet of Sofosbuvir 400mg/day and one oral tablet of Daclatasvir 60mg/day for 12 weeks.

HCV patients withGFR less than 30ml/minActive comparator

25 CKD Patients with eGFR≤30ml/min with HCV infection and will receive 2 oral tablets Qurevo®/day (Paritaprevir 150mg, Ombitasvir 25mg, Ritonavir 100mg ) and one oral capsule of Ribavirin 200mg for 12 weeks.

Drugs: SOF+DCV, OBV/PTV/r) ± ribavirin (RBV)

Sites

1 site in 1 country

  • Tanta University, Internal Medicine Department, Nephrology and Dialysis Unite and Viral CommitteeTanta, Gharbia Governorate, Egypt